Search published articles


Showing 4 results for Farahmand
IN VITRO AND IN VIVO EVALUATION OF THERAPEUTIC EFFECTS OF VINCA MAJOR ALKALOIDS ON LEISHMANIA MAJOR
M Assmar, M Farahmand, Z Aghighi, N Ghaemi, A.m Ayatollahi,
Volume 1, Issue 2 (7 2003)
Abstract
Leishmaniasis affects 1.5-2 million people annually and has been recognized as a major public health problem by the World Organization.
In Iran the incidence rate of the disease among school children in Ardestan province was 3.2 per thousand. As no effective vaccine has been found yet, control of the disease depends on effective drug therapy. The pentavalent anitmonials (pentostam and glucantime) are the current drugs of choice, but their use has been associated with side effects and a certain degree of toxicity. Furthermore, resistance towards these medications is not uncommon. For these reasons we studied the effectiveness of Vinca major alkaloids in treating Leishmania major infections both in vitro and invivo. Vinca has been used for centuries as a traditional remedy in the treatment of various diseases. The effectiveness of different concentrations of Vinca on Leishmania major promastigotes was evaluated and the results showed a significant decrease in the number of promastigotes with higher concentrations and increasing exposure times (PO.005). Results of in vivo trials showed that intralesional injections of purified extracts in chlorofromic phase induced a significant decrease in the mean lesion diameter in Balb/c mice compared to the untreated group.
Assessmnent of Potency of Oral Polio Vaccine Maintained Outside the Cold Chain in Cell Culture System
Mohammad Farahmand, Seyed Mohsen Zahraei, Mahmood Mahmoodi, Soosan Mahmoodi, Hamideh Tabatabaei, Zahra Shokati Ashkiki, Yaghoob Mplaei Kandeloosi, Maryam Yousefi, Rakhshandeh Nategh, Shohreh Shah Mahmoodi Sadeghi,
Volume 11, Issue 4 (3-2014)
Abstract
Background and Aim: Expanded program on immunization is one of the strategic universally accepted methods for control of childhood diseases including poliomyelitis. Oral Polio Vaccine (OPV) which consists of live attenuated poliovirus is considered as appropriate and most convenient tool for nation-wide vaccination. Polio virus is sensitive to heat, so OPV should be kept frozen and transferred to vaccination centers under cold chain conditions. Thermo-stability of vaccine during transportation is very important. Potency test is used to evaluate the quality and stability of vaccine. This is the first documentated study on evaluation of OPV potency kept out of cold chain conditions in Iran. Materials and Methods: To study the effects of time and temperature on potency of polio vaccine, vaccine vials were exposed to 24°C (room temperature) and 37°C (average temperature in tropical regions) for one to seven days. Vaccine potency evaluation was performed according to World Health Organization protocol. Results: It can be inferred from comparison of the results of this study with the international standards that OPV is stable at 37◦C for only one day, but if it is exposed to room temperature for 4-5 days, serotypes 1 and 2 remain unaltered but serotype 3 will lose its potency to a great extent. Conclusions: Although Polio viruses are relatively resistant to environmental conditions, their sensitivity to heat is the reason to transport the vaccine, which contains live attenuated virus, under cold chain conditions. This will prevent the titer of the vaccine virus to decrease. Vaccine stored at temperature below 4°C is preferred, otherwise the vaccine kept at room temperature (24°C) is useable for 4-5 days, and at 37◦C the vaccine is potent only for one day.
The Impact of an Educational Program Based on the Health Belief Model on Diabetic Foot Care in Type-2 Diabetic Patients
Zahra Farahmand, Davoud Shojaeizadeh, Azar Tol, Kamal Azam,
Volume 15, Issue 2 (9-2017)
Abstract
Background and Aim: Diabetes mellitus (DM) is one of the most common public health problems worldwide. Diabetic foot as a late complication of DM imposes high physical and emotional costs to the patients. The purpose of this study was to determine the effect of an educational program based on the Health Belief Model (HBM) on diabetic foot care in type-2 DM patients.
Materials and Methods: Ninety seven (female=57, male=40) type-2 diabetes patients, randomly divided into two groups ̶ and intervention (n = 47) and a control group (n = 50) ̶   participated in this study. Using questionnaires data were collected, initially and 3 months after the educational intervention, on demographic characteristics, awareness and the HBM constructs. The intervention group participated in 3 educational sessions during the3-month period. The data were analyzed by SPSS 20, the statistical test being Shapiro-Wilk, Chi-Square, Wilcoxon, McNemar tests and paired T-Test.
Results: There were no statistically significant differences before the intervention between the experimental and control groups with respect to the mean scores of knowledge and HBM’s components (perceived susceptibility, severity, benefits and barriers, as well as self-efficacy and self-care). The intervention improved the scores significantly in the experimental groups (p<0.05), while there were no significant changes in the control group scores (p>0.05). 
Conclusion: This study shows that type-2 diabetic patients need to learn how to take care of their feet and that implementing educational programs based on the Health Belief Model can be effective in this regard.
 
Prevalence and Distribution of Common Rotavirus Genotypes in Iran and Comparing them with Vaccine Strains Before the Start of the National Vaccination Program
Somayeh Jalilvand, Atefeh Kachooei, Tayebeh Latifi, Mahdieh Motamedi‐rad, Mohammad Farahmand, Nasir Mohajel, Zabihollah Shoja,
Volume 21, Issue 2 (9-2023)
Abstract
 
1. Franco MA, Angel J, Greenberg HB. Immunity and correlates of protection for rotavirus vaccines. Vaccine. 2006; 24(15):2718-31.
2. Glass RI, Parashar UD, Bresee JS, Turcios R, Fischer TK, Widdowson M-A, et al. Rotavirus vaccines: current prospects and future challenges. The Lancet. 2006;368(9532):323-32.
3. Parashar UD, Gibson CJ, Bresee JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerging infectious diseases. 2006;12(2):304.
4. Kargar M, Zare M, Najafi A. Molecular epidemiology of rotavirus strains circulating among children with gastroenteritis in Iran. Iranian journal of pediatrics. 2012;22(1):63.
5. Modares S, Rahbarimanesh AA, Karimi M, Modares S, Motamedirad M, Sohrabi A, et al. Electrophoretic RNA genomic profiles of rotavirus strains prevailing among hospitalized children with acute gastroenteritis in Tehran, Iran. 2008.
6. Shoja Z, Jalilvand S, Mokhtari-Azad T, Nategh R. Epidemiology of cocirculating human rotaviruses in Iran. The pediatric infectious disease journal. 2013;32(4):e178-e81.
7. Jalilvand S, Roohvand F, Arashkia A, Shoja Z. Update on Epidemiology and Circulating Genotypes of Rotavirus in Iranian Children With Severe Diarrhea: 1986-2015. Int J Travel Med Glob Health. 2018;6(1):7-10.
8. Desselberger U. Rotaviruses. Virus research. 2014;190:75-96.
9. http://rega.kuleuven.be/cev/ viralmetagenomics/virus-classification/ rcwg. updated 25 Mar, 2021 [.
10. Santos N, Hoshino Y. Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccine. Reviews in medical virology. 2005;15(1):29-56.
11. Banyai K, Laszlo B, Duque J, Steele AD, Nelson EA, Gentsch JR, et al. Systematic review of regional and temporal trends in global rotavirus strain diversity in the pre rotavirus vaccine era: insights for understanding the impact of rotavirus vaccination programs. Vaccine. 2012;30(1):A122-30.
12. Doro R, Laszlo B, Martella V, Leshem E, Gentsch J, Parashar U, et al. Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: is there evidence of strain selection from vaccine pressure? Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2014;28:446-61.
13. Mwanga MJ, Owor BE, Ochieng JB, Ngama MH, Ogwel B, Onyango C, et al. Rotavirus group A genotype circulation patterns across Kenya before and after nationwide vaccine introduction, 2010-2018. BMC infectious diseases. 2020;20(1):1-12.
14. Matthijnssens J, Mino S, Papp H, Potgieter C, Novo L, Heylen E, et al. Complete molecular genome analyses of equine rotavirus A strains from different continents reveal several novel genotypes and a largely conserved genotype constellation. The Journal of general virology. 2012;93(Pt 4):866-75.
15. Matthijnssens J, Ciarlet M, Rahman M, Attoui H, Banyai K, Estes MK, et al. Recommendations for the classification of group A rotaviruses using all 11 genomic RNA segments. Archives of virology. 2008;153(8):1621-9.
16. Hutson AM, Atmar RL, Graham DY, Estes MK. Norwalk Virus Infection and Disease Is Associated with ABO Histo-Blood Group Type. The Journal of Infectious Diseases. 2002;185(9):1335-7.
17. Carlsson B, Kindberg E, Buesa J, Rydell GE, Lidón MF, Montava R, et al. The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS One. 2009;4(5):e5593.
18. Tan M, Jiang X. Histo-blood group antigens: a common niche for norovirus and rotavirus. Expert reviews in molecular medicine. 2014;16.
19. Liu Y, Ramelot TA, Huang P, Liu Y, Li Z, Feizi T, et al. Glycan Specificity of P[19] Rotavirus and Comparison with Those of Related P Genotypes. J Virol. 2016;90(21):9983-96.
20. Hu L, Sankaran B, Laucirica DR, Patil K, Salmen W, Ferreon ACM, et al. Glycan recognition in globally dominant human rotaviruses. Nat Commun. 2018;9(1):2631.
21. Yen C, Steiner CA, Barrett M, Curns AT, Hunter K, Wilson E, et al. Racial disparities in diarrhea-associated hospitalizations among children in five US States, before and after introduction of rotavirus vaccine. Vaccine. 2010;28(46):7423-6.
22. Payne DC, Currier RL, Staat MA, Sahni LC, Selvarangan R, Halasa NB, et al. Epidemiologic Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA pediatrics. 2015;169(11):1040-5.
23. Shoja Z, Jalilvand S, Mokhtari-Azad T, Nategh R. Epidemiology of cocirculating human rotaviruses in Iran. The Pediatric infectious disease journal. 2013;32(4):e178-81.
24. Shoja Z, Jalilvand S, Mollaei-Kandelous Y, Validi M. Epidemiology of viral gastroenteritis in Iran. The Pediatric infectious disease journal. 2014;33(2):218-20.
25. Kachooei A, Tava Koli A, Minaeian S, Hosseini M, Jalilvand S, Latifi T, et al. Molecular characterization of rotavirus infections in children less than 5 years of age with acute gastroenteritis in Tehran, Iran, 2021–2022: Emergence of uncommon G9P [4] and G9P [8] rotavirus strains. Journal of medical virology. 2023;95(2):e2852.
26. Motamedi-Rad M, Farahmand M, Arashkia A, Jalilvand S, Shoja Z. VP7 and VP4 genotypes of rotaviruses cocirculating in Iran, 2015 to 2017: Comparison with cogent sequences of Rotarix and RotaTeq vaccine strains before their use for universal mass vaccination. Journal of medical virology. 2020;92(8):1110-23.
27. Jalilvand S, Afchangi A, Mohajel N, Roohvand F, Shoja Z. Diversity of VP7 genes of G1 rotaviruses isolated in Iran, 2009-2013. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016;37:275-9.
28. Morozova OV, Sashina TA, Fomina SG, Novikova NA. Comparative characteristics of the VP7 and VP4 antigenic epitopes of the rotaviruses circulating in Russia (Nizhny Novgorod) and the Rotarix and RotaTeq vaccines. Archives of virology. 2015;160(7):1693-703.
29. Mouna BH, Hamida-Rebai MB, Heylen E, Zeller M, Moussa A, Kacem S, et al. Sequence and phylogenetic analyses of human rotavirus strains: comparison of VP7 and VP8( *) antigenic epitopes between Tunisian and vaccine strains before national rotavirus vaccine introduction. Infection, genetics and evolution: journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2013;18:132-44.
30. Zeller M, Patton JT, Heylen E, De Coster S, Ciarlet M, Van Ranst M, et al. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq. Journal of clinical microbiology. 2011; 50(3):966-976.
31. Hoshino Y, Jones RW, Ross J, Honma S, Santos N, Gentsch JR, et al. Rotavirus serotype G9 strains belonging to VP7 gene phylogenetic sequence lineage 1 may be more suitable for serotype G9 vaccine candidates than those belonging to lineage 2 or 3. Journal of virology. 2004;78(14):7795-802.
32. Jin Q, Ward RL, Knowlton DR, Gabbay YB, Linhares AC, Rappaport R, et al. Divergence of VP7 genes of G1 rotaviruses isolated from infants vaccinated with reassortant rhesus rotaviruses. Archives of virology. 1996;141(11):2057-76.
33. Bányai K, Gentsch JR, Martella V, Bogdán Á, Havasi V, Kisfali P, et al. Trends in the epidemiology of human G1P [8] rotaviruses: a Hungarian study. The Journal of infectious diseases. 2009; 200 (1):S222-S7.
34. Magagula NB, Esona MD, Nyaga MM, Stucker KM, Halpin RA, Stockwell TB, et al. Whole genome analyses of G1P [8] rotavirus strains from vaccinated and non‐vaccinated South African children presenting with diarrhea. Journal of medical virology. 2015;87(1):79-101.
35. Kulkarni R, Arora R, Arora R, Chitambar SD. Sequence analysis of VP7 and VP4 genes of G1P [8] rotaviruses circulating among diarrhoeic children in Pune, India: A comparison with Rotarix and RotaTeq vaccine strains. Vaccine. 2014;32:A75-A83.
36. Zeller M, Patton JT, Heylen E, De Coster S, Ciarlet M, Van Ranst M, et al. Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in belgium and rotaviruses in rotarix™ and RotaTeq™. Journal of clinical microbiology. 2011:JCM. 05590-11.
37. Farahmand M, Jalilvand S, Arashkia A, Shahmahmoodi S, Afchangi A, Mollaei-Kandelous Y, et al. Association between circulating rotavirus genotypes and histo-blood group antigens (HBGAs) in the children hospitalized with acute gastroenteritis in Iran. Journal of medical virology. 2021;93(8):7.
38. Ayouni S, Sdiri-Loulizi K, de Rougemont A, Estienney M, Ambert-Balay K, Aho S, et al. Rotavirus P[8] Infections in Persons with Secretor and Nonsecretor Phenotypes, Tunisia. Emerging infectious diseases. 2015;21(11):2055-8.
39. Nordgren J, Sharma S, Bucardo F, Nasir W, Gunaydin G, Ouermi D, et al. Both Lewis and secretor status mediate susceptibility to rotavirus infections in a rotavirus genotype-dependent manner. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2014;59(11):1567-73.
40. Yu Y, Lasanajak Y, Song X, Hu L, Ramani S, Mickum ML, et al. Human milk contains novel glycans that are potential decoy receptors for neonatal rotaviruses. Molecular & cellular proteomics: MCP. 2014;13(11):2944-60.
41. Huang P, Xia M, Tan M, Zhong W, Wei C, Wang L, et al. Spike protein VP8* of human rotavirus recognizes histo-blood group antigens in a type-specific manner. Journal of virology. 2012;86(9):4833-43.
42. Parker EP, Ramani S, Lopman BA, Church JA, Iturriza-Gomara M, Prendergast AJ, et al. Causes of impaired oral vaccine efficacy in developing countries. Future microbiology. 2018;13:97-118.









Prevalence and Distribution of Common Rotavirus Genotypes in Iran and Comparing them with Vaccine Strains Before the Start of the National Vaccination Program

Somayeh Jalilvan1, Atefeh Kachooei2, Tayebeh Latifi3, Mahdieh Motamedi‐Rad4, Mohammad Farahmand3, Nasir Mohajel5, Zabihollah Shoja6*
1- Ph.D. Associate Professor, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2- Ph.D. Department of Virology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3- Ph.D. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
4- MSc. Department of Virology, Pasteur Institute of Iran, Tehran, Iran
5- Ph.D. Assistant Professor, Department of Virology, Pasteur Institute of Iran, Tehran, Iran
6- Ph.D. Associate Professor, Department of Virology, Pasteur Institute of Iran, Tehran, Iran
* Corresponding author: zabihollahshoja@gmail.com, zshoja@alumnus.tums.ac.ir
Received: May 25, 2023                                                Accepted: Oct 11, 2023

ABSTRACT
Background and Aim: Since the discovery of rotaviruses in 1973, these viruses have been identified as one of the most important and common causes of diarrhea in infants and children all over the world. Before the introduction of rotavirus vaccination, this virus led to the death of more than 500,000 children in the world annually, which mainly occurs in developing countries. With the introduction of Rotarix and RotaTeq vaccines as well as ROTAVAC and ROTASIIL in the world, the death rate has decreased by 50%. Iran, like many countries, is in the period before rotavirus vaccination, and considering putting the rotavirus vaccine in the vaccination program is one of the priorities of the country's health system. Therefore, knowing the genotypes circulating in Iran in the past and recent years and their comparison with vaccine strains is very important. Our aim in the current study is to review the prevalence of rotavirus and its genotypes circulating in Iran and whether the existing vaccines based on the circulating strains in Iran can be effective.
Materials and Methods: Studies regard to the prevalence and genotypes of rotavirus in Iran were reviewed.
Results:  G1P[8] genotype includes more than 50% of circulating genotypes. Non-G1P[8] genotypes, including G4P[8], G3P[8] and G9P[8], have also had a high frequency in some studies. In addition, in a recent study, it has been shown that the rare and uncommon genotype G9P[4] has been introduced as a common genotype.
Conclusion: Studies in Iran have shown that the country may face a change in the rotavirus genotype pattern in the future. This study can provide useful information to recommend appropriate policies for rotavirus vaccination before the start of the national vaccination program and may even change policies for the use of existing vaccines.
 
Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb